Intra-Cellular Therapies acquisition will expand J&J’s presence in neurology space, says… EP News Bureau Jan 17, 2025 GlobalData forecasts that, as a therapy for schizophrenia, Caplyta could drive sales of approximately $229 million by 2033 in the…
